News • Friend and foe in one
Breast cancer: The paradoxical role of white blood cells
White blood cells found in breast tumors can both help and hinder the spread of cancer cells to other organs, a new study from Karolinska Institutet shows.
White blood cells found in breast tumors can both help and hinder the spread of cancer cells to other organs, a new study from Karolinska Institutet shows.
New research suggests a new approach to precision radiotherapy can reduce the risk of swallowing problems for patients, without impacting the success of treatment.
Bioethics researchers call on medical societies, government leaders, clinicians, and researchers to work together to ensure AI-driven healthcare preserves patient autonomy and respects human dignity.
New trial results suggest that a short course of induction chemotherapy prior to chemoradiation could reduce the rate of relapse and death among patients with locally advanced cervical cancer.
Clinicians who show more empathy promote better psychological health among breast cancer patients, according to a new US study examining how oncology doctors facilitate psychological well-being.
US researchers have discovered that radiation therapy combined with two types of immunotherapy can control tumors in preclinical models of triple negative breast cancer.
For the first time, researchers show that AI-based predictions can deliver comparable results to clinical tests on biopsies of patients with colorectal cancer (CRC).
Experts from Brigham and Women’s Hospital have tasked ChatGPT to generate recommendations for cancer treatment – with some promise, but ultimately inadequate results.
A new analysis exploring the finances of bringing new cancer drugs to market has found that precision oncology drugs could be $1 billion cheaper to develop than non-precision drugs.
Experts presented state-of-the-art and emerging techniques to treat chest tumours and discussed common issues in the management of pneumothorax at RSNA 2022. Current ablation methods in the thorax include radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation (CRYO), irreversible electroporation (IRE) and pulsed electric field.
While screening programs for several of the commonest cancers are now well established, lung cancer screening has yet to reach anywhere near the same proportion of at-risk patients.
Genomic sequencing panels as part of personalised cancer treatment have been found to only benefit one in 20 patients they are currently used for, according to a study by CNIO.
Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy treatment that re-engineers a patient’s own T-cells to help them attack malignant tumour cells. It has been very effective in the treatment of blood cancers, including certain types of leukaemia and lymphoma. However, two serious side effects are common as a result of the treatment: cytokine release syndrome (CRS) and immune…
Unanswered questions are hampering clinicians in their efforts to get the best out of a precision medicine approach for their patients. Speaking at the Genomics and Precision Medicine Expo in London at the end of May, cancer educator Dr Elaine Vickers said the benefits of being matched to an investigational drug remain questionable for most people with advanced cancer.
Gene alterations in biliary tract cancer offer potential targets for current or future precision therapies. This is demonstrated by a new study from Vienna.
New research from the University of Helsinki increases the understanding of ovarian cancer: the identification of new subtypes could help discover new treatments.
Patients with early-stage breast cancer who have an elevated risk of having tumour recurrence now have the option to take a course of radiotherapy following breast conservation surgery that is only three weeks long, half the time of conventional radiotherapy treatment.
Dunlee unveiled its new oncology bundles onsite at ECR. The bundles combine components that have been tested and verified to work together so clinicians can offer state-of-the-art onboard Cone Beam CT (CBCT) in facilities.
A new clinical trial has shown that men diagnosed with prostate cancer can benefit from ‘radical radiotherapy’ that delivers treatment in five hospital visits instead of the typical 20.